Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA.
Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, USA.
Kidney Int. 2024 Jan;105(1):31-34. doi: 10.1016/j.kint.2023.09.001.
The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases was published in 2021. Since then, the pace of drug development for glomerular diseases has accelerated, due in large part to rapidly accumulating insights into disease pathogenesis from genetic and molecular studies of afflicted patients. To keep the Glomerular Diseases Guideline as current as possible, KDIGO made a commitment to the nephrology community to provide periodic updates, based on new developments for each disease. After the 2021 guideline was published, two novel drugs received regulatory approval for the management of lupus nephritis, leading to the first KDIGO guideline update. Herein, an executive summary of the most important guideline changes from the Lupus Nephritis chapter is provided as a quick reference.
《肾脏病：改善全球预后组织（KDIGO）肾小球疾病管理临床实践指南》于 2021 年发布。此后，由于从受影响患者的遗传和分子研究中快速获得了对疾病发病机制的深入了解，肾小球疾病的药物研发步伐加快。为了使肾小球疾病指南保持最新，KDIGO 向肾脏病学界承诺，根据每种疾病的新进展，定期提供更新。2021 年指南发布后，两种新型药物获得监管部门批准用于治疗狼疮性肾炎，从而进行了首次 KDIGO 指南更新。本文提供了狼疮性肾炎章节中最重要的指南变更摘要，作为快速参考。
